These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 26431767)

  • 21. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
    Woudstra P; Grundeken MJ; Kraak RP; Hassell ME; Arkenbout EK; Baan J; Vis MM; Koch KT; Tijssen JG; Piek JJ; de Winter RJ; Henriques JP; Wykrzykowska JJ
    Am Heart J; 2014 Feb; 167(2):133-40. PubMed ID: 24439973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
    Kraak RP; Hassell ME; Grundeken MJ; Koch KT; Henriques JP; Piek JJ; Baan J; Vis MM; Arkenbout EK; Tijssen JG; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Feb; 10(10):1160-8. PubMed ID: 25136885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
    Capodanno D; Gori T; Nef H; Latib A; Mehilli J; Lesiak M; Caramanno G; Naber C; Di Mario C; Colombo A; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Pyxaras S; Mattesini A; Naganuma T; Münzel T; Tamburino C
    EuroIntervention; 2015 Feb; 10(10):1144-53. PubMed ID: 25042421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study design and rationale.
    Testa L; Biondi Zoccai G; Tomai F; Ribichini F; Indolfi C; Tamburino C; Bartorelli A; Petronio AS; Bedogni F; De Carlo M
    J Cardiovasc Med (Hagerstown); 2015 Mar; 16(3):253-8. PubMed ID: 25469734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Full-plastic jacket" with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413).
    Tarantini G; Masiero G; Fovino LN; Mojoli M; Varricchio A; Loi B; Gistri R; Misuraca L; Gabrielli G; Cortese B; Pisano F; Moretti L; Tumminello G; Olivari Z; Mazzarotto P; Colombo A; Calabrò P; Nicolino A; Tellaroli P; Corrado D; Durante A; Steffenino G;
    Int J Cardiol; 2018 Sep; 266():67-74. PubMed ID: 29887475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials.
    Shreenivas S; Kereiakes DJ; Ellis SG; Gao R; Kimura T; Onuma Y; Piard-Ruster K; Zhang Y; Koo K; Vu MT; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1881-1890. PubMed ID: 28935081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
    Wykrzykowska JJ; Kraak RP; Hofma SH; van der Schaaf RJ; Arkenbout EK; IJsselmuiden AJ; Elias J; van Dongen IM; Tijssen RYG; Koch KT; Baan J; Vis MM; de Winter RJ; Piek JJ; Tijssen JGP; Henriques JPS;
    N Engl J Med; 2017 Jun; 376(24):2319-2328. PubMed ID: 28402237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-year outcome of everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stents: a comprehensive updated meta-analysis of randomized controlled trials.
    Zhang H; Zhao J; Xu Y; Zhang W; Sui Y; Liu Q; Wang Y; Liu Z; Gao R; Wu Y
    Expert Rev Med Devices; 2019 May; 16(5):421-427. PubMed ID: 31008654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R.
    Mehilli J; Achenbach S; Woehrle J; Baquet M; Riemer T; Muenzel T; Nef H; Naber C; Richardt G; Zahn R; Gori T; Neumann T; Kastner J; Schmermund A; Hamm C
    EuroIntervention; 2017 Dec; 13(11):1319-1326. PubMed ID: 28649953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
    La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in Real World and Complex Coronary Disease: Procedural and 30-day Outcomes at Two Australian Centres.
    Robaei D; Back LM; Ooi SY; Pitney MR; Jepson N
    Heart Lung Circ; 2015 Sep; 24(9):854-9. PubMed ID: 25778622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice - results from the European Absorb Consortium.
    Wiebe J; Hofmann FJ; West N; Baumbach A; Carrie D; Bermudez EP; Cayla G; Hernandez FH; de la Torre Hernandez JM; Koning R; Loi B; Moscarella E; Tarantini G; Zaman A; Lober C; Riemer T; Achenbach S; Hamm CW; Nef HM;
    Catheter Cardiovasc Interv; 2022 Feb; 99(3):533-540. PubMed ID: 34463427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population.
    Wiebe J; Gilbert F; Dörr O; Liebetrau C; Wilkens E; Bauer T; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):975-81. PubMed ID: 26269391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.